By Amanda Mao, 10-October-2017
On 8th October 2017, the Chinese government issued a ground-breaking policy to encourage innovation on review and approval of drugs and medical devices. On an expanded basis, this document is the official outcome of the CFDA’s draft regulation series on drugs and medical devices.
By Amanda Mao, 05-July-2017
China Food and Drug Administration (CFDA) was approved as a new regulatory member of the ICH in May/ June 2017. Below we at Acurit Medical Communications translate and edit information from various sources in Chinese to analyse this milestone and its impact on the sector. We especially highlight changes and trends most relevant to international companies.
By Amanda Mao, 18-May-2017
On 11 and 12 of May 2017, China Food and Drug Administration (FDA) announced on its official website four new draft regulations on drugs and medical devices. All drafts are currently inviting public comments. We translate the main contents from Chinese into English, focusing on the possible impact on overseas companies.
By Amanda Mao, 12-Apr-2017
In China, old-age dependency ratio will increase from the current 2.8:1 to 1.3:1 in 2050. On the other hand, the aged care industry still needs to be revitalised. Senile finance, supplies, services and real estate are all in infancy, with huge potential to grow.This, in turn, leaves massive room for aged care businesses overseas to plan their China market entry.
By Amanda Mao, 20-Mar-2017, updated 11-Oct-2017
The draft regulation was approved by CFDA on 20–Jun-2017 and published on 11-Oct-2017, under the title of No. 35 CFDA Degree. There are only minor revisions compared to the original statements. This regulation will bring about far-reaching and profound effects for China pharmaceutical market for imported drugs.